Identification of New GPCR Targets in NET Cell Lines Using Ligand Screening Abstract #624

Introduction: Although somatostatin analogs constitute an important part of current therapeutic strategies, both hypersecretion and proliferation of NETs cannot be controlled efficiently in many patients. Identifying and dissecting new molecular targets and regulatory pathways may help to improve diagnostic and therapeutic options for NET patients.
Aim(s): This study was focused on identifying new G protein-coupled receptor (GPCR) targets on neuroendocrine tumor cells, with special attention to peptide GPCRs and receptors for licenced drugs. Their role in NET cell signaling, secretion and proliferation was studied.
Materials and methods: A ligand screen involving 1,200 peptide and small-molecule ligands was carried out on six permanent cell lines derived from human NETs, among them BON and H727 cells. Dynamic mass redistribution, calcium and cAMP were measured to screen or confirm reactivities of ligands, including specific analogs or antagonists. Proliferation was measured using DAPI HCA or BrDU staining, secretion by ELISA assays.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Carsten Grötzinger

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2984 AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy
Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
Authors: Grötzinger C, Exner S, Schuldt C, Du J, ...
#316 Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia
Introduction: Despite an increasing incidence, a paucity of biological information has led to major limitations in identification of plausible therapeutic targets for small intestinal neuroendocrine tumors (SINETs)
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Olfat Kamel Hasan
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt